Regorafenib increases overall survival in hepatocellular carcinoma study
29 June 2016 | By Victoria White, Digital Content Producer
Results from the Phase III RESORCE trial investigating Bayer’s regorafenib in patients with unresectable hepatocellular carcinoma have been announced...